EMA Authorised: Pyzchiva (ustekinumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

EMA authorised Pyzchiva (ustekinumab) for Crohn's disease, ulcerative colitis, and psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• Pyzchiva (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Crohn Disease;Colitis, Ulcerative;Arthritis, Psoriatic. MAH: Samsung Bioepis NL B.V.. Decision date: 03/11/2025